C

Contineum Therapeutics Inc
NASDAQ:CTNM

Watchlist Manager
Contineum Therapeutics Inc
NASDAQ:CTNM
Watchlist
Price: 14.6 USD 1.18% Market Closed
Market Cap: $426m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Contineum Therapeutics Inc
NASDAQ:CTNM
426.1m USD
Loading...
IN
Aaswa Trading and Exports Ltd
BSE:512038
26.9T INR
Loading...
US
GE Vernova LLC
NYSE:GEV
193.6B USD
Loading...
UK
Eight Capital Partners PLC
F:ECS
158.4B EUR
Loading...
US
China Industrial Group Inc
OTC:CIND
121B USD
Loading...
US
Schlumberger NV
NYSE:SLB
72B USD
Loading...
US
Baker Hughes Co
NASDAQ:BKR
55.2B USD
Loading...
IN
GTV Engineering Ltd
BSE:539479
4.5T INR
Loading...
US
CoreWeave Inc
NASDAQ:CRWV
46.2B USD
Loading...
CH
Galderma Group AG
SIX:GALD
34.1B CHF
Loading...
US
Reddit Inc
NYSE:RDDT
34.2B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Contineum Therapeutics Inc
Glance View

Market Cap
426m USD
Industry
N/A

Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).

CTNM Intrinsic Value
3.54 USD
Overvaluation 76%
Intrinsic Value
Price
C
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top